Cargando…
Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma
Fumarate hydratase (FH) - deficient renal cell carcinoma (FHdRCC) is a rare aggressive subtype of RCC caused by a germline or sporadic loss-of-function mutation in the FH gene. Here, we summarize how FH deficiency results in the accumulation of fumarate, which in turn leads to activation of hypoxia-...
Autores principales: | Lindner, Andrea Katharina, Tulchiner, Gennadi, Seeber, Andreas, Siska, Peter J., Thurnher, Martin, Pichler, Renate |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9337267/ https://www.ncbi.nlm.nih.gov/pubmed/35912170 http://dx.doi.org/10.3389/fonc.2022.906014 |
Ejemplares similares
-
Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case report
por: Lindner, Andrea Katharina, et al.
Publicado: (2018) -
Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma
por: Tulchiner, Gennadi, et al.
Publicado: (2021) -
CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma
por: Tulchiner, Gennadi, et al.
Publicado: (2021) -
Tubulocystic renal cell carcinoma with poorly differentiated foci and loss of fumarate hydratase: A case report
por: Al-Hussain, Turki O., et al.
Publicado: (2020) -
Structural basis of fumarate hydratase deficiency
por: Picaud, Sarah, et al.
Publicado: (2011)